Cadila Healthcare Ltd (Zydus Cadila), through its fully-owned subsidiary Zydus Animal Health Ltd (ZAHL), has signed a share purchase agreement with ICICI Venture to acquire 100% shareholding of Finest Procuring Solutions Ltd, which in turn holds cent percent shareholding of Bremer Pharma GmbH of Germany.

The agreement, announced on Wednesday, includes the transfer of all key assets, people, brands and export contracts of Bremer, a global animal health company headquartered in Warburg-Scherfede, Germany. However, Zydus Cadila did not disclose financial details of the transaction.

The acquisition will help Zydus AHL expand its animal health business and gain strategic access to the key markets across Europe, South America, Asia and Africa. The global animal health business is valued at $ 20 billion.

Speaking on the development, Mr Pankaj R Patel, Chairman and Managing Director, said that Bremer’s high quality, generic veterinary pharmaceutical business and extensive presence in the global markets will help Zydus Cadila leverage its strengths and add new dimensions to its growth in the animal health business.

Bremer Pharma has over 500 registrations and a network of distributors in more than 50 countries. The company has research facilities and infrastructure for manufacturing powders, tablets, liquids in Warburg-Scherfede, Germany. The plant is compliant with the EC-GMP and EHS norms. It also has an extensive quality assurance system and a DIN ISO9001:2008 certification. Bremer Pharma has been in the animal health business since 1982.

Related Topics